| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥377.4B | ¥298.4B | +26.5% |
| Operating Income | ¥156.4B | ¥105.5B | +48.2% |
| Ordinary Income | ¥157.2B | ¥107.1B | +46.8% |
| Net Income | ¥100.5B | ¥68.5B | +46.7% |
| ROE | 20.8% | 14.4% | - |
FY2026 Q3 results demonstrated robust performance with revenue of 377.4B yen (YoY +26.5%), operating income of 156.4B yen (+48.2%), ordinary income of 157.2B yen (+46.8%), and net income of 100.5B yen (+46.7%). Operating margin expanded significantly to 41.4% from 35.4% in the prior year, representing a 607 basis point improvement, while net profit margin improved 380 basis points to 26.6%. The strong profit growth outpaced revenue growth, driven by operating leverage as SG&A expense ratio declined 385 basis points to 22.2% and gross profit margin improved 221 basis points to 63.6%. Full-year guidance progress stands at approximately 92% for operating income and 91% for net income, indicating high likelihood of target achievement with potential upside.
[Profitability] ROE of 20.8% represents strong return on equity, decomposing into net profit margin of 26.6% (improved from 22.8% YoY), asset turnover of 0.629x, and financial leverage of 1.24x. Operating margin of 41.4% expanded 607 basis points from 35.4% YoY, driven by gross profit margin improvement of 221 basis points to 63.6% and SG&A expense ratio reduction of 385 basis points to 22.2%. Effective tax rate of 36.1% remains elevated but did not impede strong profit growth. [Cash Quality] Cash and deposits of 374.9B yen provide coverage of 4.0x against short-term debt, with short-term liquidity further supported by investment securities of 140.9B yen. Accounts receivable decreased sharply by 17.9B yen (down 68.1% YoY) to 8.4B yen, indicating accelerated collection and improved working capital efficiency. [Investment Efficiency] Total asset turnover of 0.629x reflects asset-light business model characteristics, with assets concentrated in liquid holdings at 62.5% cash and 23.5% investment securities. [Financial Health] Equity ratio of 80.4% improved from 77.0% YoY, current ratio of 440.5% and quick ratio of 440.5% demonstrate exceptional short-term liquidity. Debt-to-equity ratio of 0.24 and interest coverage ratio of approximately 387x indicate minimal financial risk, with long-term borrowings reduced by 19.0B yen (down 47.5%) to 21.0B yen.
Cash and deposits stood at 374.9B yen as of Q3, constituting 62.5% of total assets and providing substantial liquidity buffer. The significant reduction in accounts receivable by 17.9B yen (down 68.1% YoY) to 8.4B yen indicates strong cash collection from operating activities and improved receivables management, contributing positively to cash generation. Working capital composition shows accrued expenses of 15.8B yen and income taxes payable of 9.0B yen, representing normal operational obligations well-covered by liquid assets. Long-term borrowings decreased 19.0B yen to 21.0B yen, reflecting debt repayment activity that reduced financial leverage. The asset-light model with minimal capital expenditure requirements allows strong profit conversion to cash. Cash coverage of short-term liabilities at 4.0x provides ample cushion for operational and strategic flexibility. Investment securities holdings of 140.9B yen offer additional liquidity potential while representing 29.2% of equity, maintaining balance sheet conservatism.
Ordinary income of 157.2B yen versus operating income of 156.4B yen shows minimal non-operating net contribution of approximately 0.8B yen, indicating earnings are predominantly operating-driven. Non-operating income composition includes interest income of 1.2B yen and other financial income, partially offset by interest expense of 0.4B yen, resulting in net non-operating impact of just 0.2% of revenue. The negligible gap between operating and ordinary income confirms high-quality recurring earnings with minimal dependency on financial or extraordinary items. The sharp reduction in accounts receivable alongside strong profit growth suggests earnings are well-supported by cash collection, enhancing earnings quality. The effective tax rate of 36.1% applied to pretax income of 157.2B yen resulted in tax expense of 56.7B yen, representing a normalized tax burden without unusual adjustments. Gross profit margin expansion of 221 basis points and SG&A efficiency gains indicate sustainable operational improvements rather than one-time benefits, supporting recurring earnings quality.
Transaction closing timing concentration creates quarterly revenue volatility, as M&A advisory revenue recognition depends on deal completion schedules that may cluster unevenly across quarters. Rising personnel costs from talent acquisition and training could reverse the favorable SG&A expense ratio trend of 22.2%, particularly if revenue growth moderates while competitive pressures for skilled professionals intensify. The dividend payout ratio of approximately 97.5% based on annual dividend guidance of 29 yen leaves minimal buffer for profit fluctuations, creating potential pressure on dividend sustainability if earnings growth decelerates or if reinvestment needs increase.
[Industry Position] (Reference - Proprietary Analysis) The company demonstrates exceptional profitability relative to healthcare industry peers. Operating margin of 41.4% substantially exceeds the industry median of 8.2% (2025-Q3, IQR: 5.2%-10.9%, n=44), positioning in the top tier. Net profit margin of 26.6% significantly outperforms the industry median of 5.7% (IQR: 3.1%-9.1%), indicating superior cost structure and pricing power. ROE of 20.8% exceeds the industry median of 9.7% (IQR: 3.9%-15.0%), reflecting highly efficient capital deployment. Revenue growth of 26.5% YoY compares favorably to the industry median of 9.5% (IQR: 2.7%-15.2%), demonstrating strong market position expansion. Financial health metrics show equity ratio of 80.4% well above the industry median of 49.0% (IQR: 38.8%-66.3%), and current ratio of 440.5% far exceeds the median of 2.06x (IQR: 1.53x-2.95x), indicating conservative balance sheet management. The company's asset-light, high-margin business model characteristics diverge significantly from typical healthcare industry capital intensity and profitability profiles. (Industry: Healthcare, N=44 companies, Period: 2025-Q3, Source: Proprietary analysis)
Operating leverage materialization is evident through margin expansion across all levels, with operating margin improving 607 basis points to 41.4% as revenue growth of 26.5% significantly outpaced SG&A expense growth. The combination of gross margin improvement and SG&A efficiency gains suggests effective scaling of the business model, though sustainability depends on maintaining revenue momentum and controlling personnel costs. Full-year guidance achievement probability appears high with operating income at 92% progress and net income at 91% progress through Q3, leaving modest targets for Q4 that could enable upside delivery if deal closing momentum continues. Balance sheet strength provides strategic flexibility with cash and investment securities totaling 515.8B yen against minimal debt of 21.0B yen, enabling opportunistic investments, shareholder returns, or countercyclical resilience, though the elevated dividend payout ratio of 97.5% constrains reinvestment capacity unless profit growth continues.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.